RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
June 07 2023 - 8:00AM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage,
immunology-based therapeutics company focused on discovering,
developing and commercializing oral small molecule therapies for
patients with significant unmet needs in inflammatory diseases and
oncology, today announced that Brian Wong, M.D., Ph.D., President
and Chief Executive Officer, will participate in a fireside chat at
the Goldman Sachs Global Healthcare Conference on Monday, June 12,
2023 at 1:20 p.m. PT.
To access the live webcast or subsequent archived recording of
the discussion, please visit the RAPT Therapeutics website at
https://investors.rapt.com/events-and-presentations.
About RAPT Therapeutics, Inc.RAPT Therapeutics
is a clinical stage immunology-based therapeutics company focused
on discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in inflammatory
diseases and oncology. Utilizing its proprietary discovery and
development engine, the company is developing highly selective
small molecules designed to modulate the critical immune drivers
underlying these diseases. RAPT has discovered and advanced two
unique drug candidates, RPT193 and FLX475, each targeting C-C motif
chemokine receptor 4 (CCR4), for the treatment of inflammation and
cancer, respectively. The company is also pursuing a range of
targets that are in the discovery stage of development.
Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
Media Contact:Aljanae
Reynoldsareynolds@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2023 to Apr 2024